Credit Suisse retains Low AA credit rating on Roche.
M2 PHARMA-October 14, 2011-Credit Suisse retains Low AA credit rating on Roche(C)2011 M2 COMMUNICATIONS
14 October 2011 - Credit Suisse confirmed yesterday the Low AA credit rating with a "stable" outlook on Roche (VTX:ROG) after the Swiss company announced its revenue for the first nine months of 2011.
Credit Suisse said that the rating is based on the firm's strong business and financial profile. Despite the challenging environment, Roche's performance is solid. Main revenue contributors are oncology medicines such as Herceptin and MabThera as well as eye care product Lucentis and rheumatism drug Actemra.
Credit Suisse retained its "hold" recommendation on Roche's 2.5% bond due in 2012 and on the 4.5% bond due in 2017.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 14, 2011|
|Previous Article:||MediciNova to get USD2.5m from Kissei to expand MN-221 programme.|
|Next Article:||Beijing CDC selects Sinovac to supply Anflu for Beijing vaccination campaign.|